Cambridge, UK, 30 July 2021 – Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases.
THIS ANNOUNCEMENT IS FOR US ADS HOLDERS ONLY
Distribution Dates for shares and ADRs in Accustem Sciences Limited
Completed Covid-19 Research Project Delivers Encouraging Results
London and Boston, MA, 29 June 2021 – OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory
NEW YORK & LONDON, June 23, 2021 – Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, neurology,
Tiziana Appoints Dr. Kevin Schutz as Vice-President of Regulatory Affairs
Tiziana Responds to UK Call for Development of Innovative ‘Take Home’ Treatments for COVID-19 Disease
Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers.
Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers.
Tiziana Life Sciences Announces Initiation of Clinical Trial in a Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual
